IDEXX Laboratories (NASDAQ:IDXX) Shares Gap Up – Here’s Why

IDEXX Laboratories, Inc. (NASDAQ:IDXX) gapped up prior to trading on Monday. The stock had previously closed at $551.21, but opened at $625.00. IDEXX Laboratories shares last traded at $643.2080, with a volume of 380,773 shares trading hands.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the stock. UBS Group dropped their price objective on shares of IDEXX Laboratories from $670.00 to $627.00 and set a “neutral” rating for the company in a research note on Tuesday, October 27th. Citigroup upped their price target on IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 5th. KeyCorp began coverage on IDEXX Laboratories in a report on Monday, October 12th. They issued a “sector weight” rating on the stock. Weiss Ratings raised shares of IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, October 8th. Finally, Wall Street Zen downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Eight analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $721.67.

IDEXX Laboratories Stock Performance

The company has a 50-day moving average price of $534.27 and a 200-day moving average price of $574.09. The firm has a market capitalization of $50.41 billion, a price-to-earnings ratio of 44.79 and a beta of 1.55. The company has a quick ratio of 0.87, a current ratio of 1.17 and a debt-to-equity ratio of 0.19.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $4.27 earnings per share for the quarter, beating the consensus estimate of $3.94 by $0.33. The business had revenue of $1.22 billion during the quarter, compared to analyst estimates of $1.20 billion. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%. The company’s revenue was up 9.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $3.50 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. As a group, equities research analysts forecast that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current year.

Insider Activity

In other news, Director Lawrence D. Kingsley sold 2,203 shares of the company’s stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the completion of the sale, the director owned 9,568 shares in the company, valued at approximately $5,090,941.44. This represents a 18.72% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.79% of the company’s stock.

Institutional Investors Weigh In On IDEXX Laboratories

A number of hedge funds have recently added to or reduced their stakes in IDXX. Bank of New York Mellon Corp acquired a new stake in IDEXX Laboratories in the second quarter worth $628,223,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of IDEXX Laboratories by 4.6% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 911,489 shares of the company’s stock worth $479,844,000 after acquiring an additional 39,700 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its holdings in IDEXX Laboratories by 52.4% during the first quarter. Arrowstreet Capital Limited Partnership now owns 838,839 shares of the company’s stock valued at $471,335,000 after purchasing an additional 288,471 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in IDEXX Laboratories by 4.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 573,332 shares of the company’s stock worth $322,145,000 after acquiring an additional 23,582 shares during the period. Finally, Alyeska Investment Group L.P. boosted its position in shares of IDEXX Laboratories by 97.3% during the 2nd quarter. Alyeska Investment Group L.P. now owns 401,082 shares of the company’s stock valued at $211,146,000 after acquiring an additional 197,808 shares during the last quarter. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX’s companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.